Programmed death-1 (PD-1) inhibitors can block the binding of PD-1 and PD-L1, upregulate the growth and proliferation of T cells, enhance T cell recognition of tumor cells, and ultimately boost the body’s immune function to achieve antitumor effects (4). Here, CD274 is linked to neoplasm.